Clinical Progression, Viral Load Dynamics, and Immune Kinetics of Nipah Virus Infection: Nipah Virus Kinetics Study Protocol.

@article{farzin2026clinical,
  title = {{Clinical Progression, Viral Load Dynamics, and Immune Kinetics of Nipah Virus Infection: Nipah Virus Kinetics Study Protocol.}},
  author = {Anika Farzin and Shadman Sakib Choudhury and Wasik Rahman Aquib and Sharmin Sultana and Mintu Chowdhury and Faruq Abdulla and Arifa Nazneen and Kamal Ibne Amin Chowdhury and Tonmoy Sarkar and Dewan Imtiaz Rahman and Mohammad Mamun Alam and Md Mahfuzur Rahman and Ayesha Siddika and Tahsin Tabassum Anonto and Sinthia Karim and Md Taufiqur Rahman Bhuiyan and Christina F Spiropoulou and Michael K Lo and Trevor Shoemaker and Mohammed Ziaur Rahman and Sayera Banu and Tahmina Shirin and Firdausi Qadri and Joel M Montgomery and Syed Moinuddin Satter},
  journal = {Current protocols},
  year = {2026},
  month = oct,
  doi = {10.1002/cpz1.70508},
  url = {https://europepmc.org/article/MED/42925498},
  note = {CC BY},
}

TY  - JOUR
TI  - Clinical Progression, Viral Load Dynamics, and Immune Kinetics of Nipah Virus Infection: Nipah Virus Kinetics Study Protocol.
AU  - Anika Farzin
AU  - Shadman Sakib Choudhury
AU  - Wasik Rahman Aquib
AU  - Sharmin Sultana
AU  - Mintu Chowdhury
AU  - Faruq Abdulla
AU  - Arifa Nazneen
AU  - Kamal Ibne Amin Chowdhury
AU  - Tonmoy Sarkar
AU  - Dewan Imtiaz Rahman
AU  - Mohammad Mamun Alam
AU  - Md Mahfuzur Rahman
AU  - Ayesha Siddika
AU  - Tahsin Tabassum Anonto
AU  - Sinthia Karim
AU  - Md Taufiqur Rahman Bhuiyan
AU  - Christina F Spiropoulou
AU  - Michael K Lo
AU  - Trevor Shoemaker
AU  - Mohammed Ziaur Rahman
AU  - Sayera Banu
AU  - Tahmina Shirin
AU  - Firdausi Qadri
AU  - Joel M Montgomery
AU  - Syed Moinuddin Satter
PY  - 2026
DA  - 2026/10/01
JO  - Current protocols
DO  - 10.1002/cpz1.70508
UR  - https://europepmc.org/article/MED/42925498
AB  - Background  Nipah virus (NiV) is a zoonotic pathogen with pandemic potential. Understanding the immune response to this pathogen is important for developing vaccines and therapeutics. This study aims to characterize viral load, host immune kinetics, and biomarker progression throughout NiV infection.Methods  We will utilize the ongoing NiV surveillance platform in Bangladesh to enroll individuals with confirmed NiV infection. Oropharyngeal swabs and blood samples will be collected following the protocol. Oropharyngeal swabs will be taken daily until two consecutive negative results are obtained. Blood samples will be collected every 48 hours from initial detection of the virus until discharge from the hospital to assess IgM and IgG. Among survivors, 5 ml of blood will be collected every 15 days for 3 months from initial detection of the virus and then every 30 days up to 6 months. Viral load will be measured using RT-qPCR. Immune kinetics will be assessed using quantitative enzyme-linked immunosorbent assay (ELISA), and biomarkers will be analyzed via ELISA. Clinical progression, viral load, immune response, and biomarker patterns will be observed and documented.Discussion  The study is expected to characterize the temporal trends of viral load and immune responses and examine their association with clinical progression, epidemiological indices, and disease outcome. Findings from this study could enhance understanding of the human immune response to NiV and inform diagnostic schedules and vaccine and therapeutics development. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.
SN  - 2691-1299
ER  -